Vor Biopharma (NASDAQ:VOR) Research Coverage Started at William Blair

William Blair initiated coverage on shares of Vor Biopharma (NASDAQ:VOR) in a research note published on Wednesday morning, MarketBeat.com reports. The brokerage issued an outperform rating on the stock.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings upgraded Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 14th. Wedbush lifted their price objective on Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, August 12th. Wall Street Zen upgraded Vor Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Citigroup upgraded Vor Biopharma to a “strong-buy” rating in a research note on Thursday, October 15th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $38.00.

Vor Biopharma Stock Performance

Shares of NASDAQ VOR opened at $18.26 on Wednesday. Vor Biopharma has a 1 year low of $6.50 and a 1 year high of $28.66. The firm’s 50 day moving average price is $21.13 and its 200 day moving average price is $18.42.

Vor Biopharma (NASDAQ:VOR) last released its earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). On average, equities research analysts forecast that Vor Biopharma will post -2.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors have recently bought and sold shares of the stock. Cannon Global Investment Management LLC acquired a new position in Vor Biopharma during the first quarter worth approximately $209,000. Sei Investments Co. acquired a new position in shares of Vor Biopharma in the 1st quarter valued at $245,000. Independent Financial Group LLC acquired a new position in shares of Vor Biopharma in the 1st quarter valued at $249,000. Wellington Management Group LLP purchased a new stake in shares of Vor Biopharma during the 2nd quarter valued at $499,000. Finally, Irenic Capital Management LP purchased a new stake in shares of Vor Biopharma during the 1st quarter valued at $583,000. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell therapies for the treatment of cancer, particularly blood cancers. The company combines gene-editing technologies with targeted immunotherapies to address limitations associated with conventional cancer treatments.

Vor’s platform is designed to create engineered hematopoietic stem cells that can protect healthy blood-forming cells from targeted therapies. Its lead program, VOR33, is an investigational CD33-edited hematopoietic stem cell therapy intended to support the use of CD33-targeted treatments in patients with acute myeloid leukemia.